|
1.
|
|
17 p, 921.2 KB |
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
/
Sauta, Elisabetta (Humanitas Clinical and Research Center (Itàlia)) ;
Robin, Marie (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Bersanelli, Mateo (Department of Biomedical Sciences. Humanitas University) ;
Travaglino, Erica (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Meggendorfer, Manje (Mll Munich Leukemia Laboratory) ;
Zhao, Lin-Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Caballero Berrocal, Juan Carlos (Hematology Department. Hospital Universitario de Salamanca) ;
Sala, Claudia (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Maggioni, Giulia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bernardi, Massimo (University Vita-Salute San Raffaele (Itàlia)) ;
Di Grazia, Carmen (Irccs Ospedale Policlinico San Martino) ;
Vago, Luca (University Vita-Salute San Raffaele (Itàlia)) ;
Rivoli, Giulia (Irccs Ospedale Policlinico San Martino) ;
Borin, Lorenza (Ospedale San Gerardo) ;
D'Amico, Saverio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Tentori, Cristina Astrid (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Ubezio, Marta (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Campagna, Alessia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Russo, Antonio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Mannina, Daniele (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Lanino, Luca (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Chiusolo, Patrizia (Università Cattolica Del Sacro Cuore) ;
Giaccone, Luisa (Department of Molecular Biotechnology and Health Sciences. University of Turin) ;
Voso, Maria Teresa (Tor Vergata University) ;
Riva, Maria (Asst Grande Ospedale Metropolitano Niguarda) ;
Oliva, Esther Natalie (Grande Ospedale Metropolitano Bianchi Melacrino Morelli) ;
Zampini, Matteo (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Riva, Elena (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Nibourel, Olivier (Chu Lille) ;
Bicchieri, Marinela (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bolli, Niccolo (Department of Oncology and Hemato-Oncology. University of Milan) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni Xxiii) ;
Passamonti, Francesco (Department of Medicine and Surgery. University of Insubria) ;
Savevski, Victor (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Santoro, Armando (Department of Biomedical Sciences. Humanitas University) ;
Germing, Ulrich (Department of Hematology. Heinrich-Heine-University. University Clinic) ;
Kordasti, Shahram (Hematology Department. DISCLIMO-Università Politecnica Delle Marche) ;
Santini, Valeria (University of Florence) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Sole, F (Institut de Recerca Contra la Leucèmia Josep Carreras) ;
Kern, Wolfgang (Mll Munich Leukemia Laboratory) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Arenillas, Leonor (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Fenaux, Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Haferlach, Torsten (Mll Munich Leukemia Laboratory) ;
Castellani, Gastone (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Della Porta, Matteo Giovanni (Department of Biomedical Sciences. Humanitas University)
PURPOSEMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). [...]
2023 -  10.1200/JCO.22.01784
Journal of Clinical Oncology, Vol. 41 Núm. 15 (20 2023) , p. 2827-2842
|
|
|
2.
|
|
10 p, 345.6 KB |
Momelotinib long-term safety and survival in myelofibrosis : integrated analysis of phase 3 randomized controlled trials
/
Verstovsek, Srdan (The University of Texas, USA) ;
Mesa, Ruben (UT Health San Antonio Cancer Center, San Antonio, USA) ;
Gupta, Vikas (Princess Margaret Cancer Centre, Toronto, Canada) ;
Lavie, David (Hadassah-Hebrew University Medical Center, Jerusalem, Israel) ;
Dubruille, Viviane (Centre Hospitalier Universitaire de Nantes (CHU de Nantes), Nantes, France) ;
Cambier, Nathalie (Centre hospitalier r ' egional universitaire de Lille (CHRU Lille), Lille, France) ;
Platzbecker, Uwe (University of Leipzig, Germany) ;
Hus, Marek (Uniwersytet Medyczny w Lublinie, Lublin, Poland) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Oh, Stephen T. (Washington University School of Medicine, St. Louis, USA) ;
Kiladjian, Jean Jacques (Universite de Paris, France) ;
Vannucchi, Alessandro M. (University of Florence, Careggi University Hospital, Florence, Italy) ;
Gerds, Aaron (Cleveland Clinic, USA) ;
Egyed, Miklos (Teaching Hospital Mor Kaposi, Kaposv ' ar, Hungary) ;
Mayer, Jiří (Masaryk University, Brno, Czech Republic) ;
Sacha, Tomasz (Uniwersytet Jagiellonski Collegium Medicum, Krakow, Poland) ;
Kawashima, Jun (Sierra Oncology, San Mateo, CA) ;
Morris, Marc (Sierra Oncology, San Mateo, CA) ;
Huang, Mei (Sierra Oncology, San Mateo, CA) ;
Harrison, Claire (National Health Services (NHS) Foundation Trust, London, United Kingdom)
Momelotinib is the first inhibitor of Janus kinase 1 (JAK1) and JAK2 shown to also inhibit activin A receptor type 1 (ACVR1), a key regulator of iron homeostasis, and has demonstrated improvements in splenomegaly, constitutional symptoms, and anemia in myelofibrosis (MF). [...]
2023 - 10.1182/bloodadvances.2022009311
Blood advances, Vol. 7 Núm. 14 (july 2023) , p. 3582-3591
|
|
|
3.
|
|
15 p, 1.6 MB |
The ABNL-MARRO 001 study : a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes
/
Moyo, Tamara K. (Vanderbilt University School of Medicine) ;
Mendler, Jason H (University of Rochester Medical Center) ;
Itzykson, Raphael (Paris Diderot University) ;
Kishtagari, Ashwin (Vanderbilt University School of Medicine) ;
Solary, Eric (Institut Gustave Roussy. Université Paris-Saclay) ;
Seegmiller, Adam C. (Vanderbilt University School of Medicine) ;
Gerds, Aaron T. (Cleveland Clinic) ;
Ayers, Gregory D. (Vanderbilt University School of Medicine) ;
Dezern, Amy E. (Johns Hopkins University) ;
Nazha, Aziz (Cleveland Clinic) ;
Valent, Peter (Ludwig Boltzmann Institute for Hematology and Oncology. Medical University of Vienna) ;
Onida, Francesco (University of Milan) ;
Van Azizan de Loosdrecht, Arjan A. (Amsterdam UMC. University Medical Center) ;
Pleyer, Lisa (Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials) ;
Xicoy Cirici, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Tibes, Raoul (Mayo Clinic) ;
Geissler, Klaus (Sigmund Freud University) ;
Komrokji, Rami S. (H. Lee Moffitt Cancer Center) ;
Zhang, Jing (University of Wisconsin-Madison) ;
Germing, Ulrich (Department of Hematology. Oncology. and Clinical Immunology. University of Duesseldorf) ;
Steensma, David P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Wiseman, Daniel H. (University of Manchester) ;
Pfeilstöecker, Michael (Hanusch Hospital and Ludwig Boltzmann Institute for Hematology and Oncology) ;
Elena, Chiara (University of Pavia) ;
Cross, Nicholas C P (University of Southampton) ;
Luebbert, Michael (University of Freiburg) ;
Mesa, Ruben A. (Mays Cancer Center at UT Health San Antonio MD Anderson) ;
Montalban-Bravo, Guillermo (MD Anderson Cancer Center) ;
Sanz, G.F. (Hospital Universitari i Politècnic La Fe (València)) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Patnaik, Mrinal M. (Mayo Clinic) ;
Padron, Eric (H. Lee Moffitt Cancer Center) ;
Santini, Valeria (University of Florence) ;
Fenaux, Pierre (Paris Diderot University) ;
Savona, Michael R. (Vanderbilt University School of Medicine) ;
Universitat Autònoma de Barcelona
Background: Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) comprise several rare hematologic malignancies with shared concomitant dysplastic and proliferative clinicopathologic features of bone marrow failure and propensity of acute leukemic transformation, and have significant impact on patient quality of life. [...]
2022 - 10.1186/s12885-022-10073-w
BMC Cancer, Vol. 22 Núm. 1 (december 2022) , p. 1013
|
|
|
4.
|
|
1 p, 257.6 KB |
Publisher Correction : Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study
/
Kayser, Sabine (Heidelberg University Hospital (Alemanya)) ;
Rahmé, Ramy (Université Paris Diderot. Hôpital Saint Louis) ;
Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ;
Ghiaur, Gabriel (Johns Hopkins University) ;
Thomas, Xavier (Centre Hospitalier Lyon-Sud) ;
Guerci-Bresler, Agnes (Nancy University Hospital) ;
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Pigneux, Arnaud (Bordeaux University Hospital (França)) ;
Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Raffoux, Emmanuel (Université Paris Diderot) ;
Tormo, Mar (Universitat de València) ;
Vey, Norbert (Institut Paoli Calmette) ;
de la Serna, Javier (Hospital Universitario 12 de Octubre (Madrid)) ;
Salamero, Olga (Hospital Universitari Vall d'Hebron) ;
Lengfelder, Eva (University Hospital Mannheim (Alemanya)) ;
Levis, Mark (Johns Hopkins University) ;
Fenaux, Pierre (Université Paris Diderot) ;
Sanz, Miguel A.. (Centro de Investigación Biomédica en Red de Cáncer) ;
Platzbecker, Uwe (University Hospital Leipzig. Medical Clinic and Policlinic I, Hematology and Cellular Therapy) ;
Schlenk, Richard F. (NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital) ;
Adès, Lionel (Université Paris Diderot) ;
Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ;
Universitat Autònoma de Barcelona
2021 - 10.1038/s41375-021-01358-3
Leukemia, Vol. 35 (november 2021) , p. 3631
|
|
|
5.
|
|
9 p, 621.5 KB |
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study
/
Kayser, Sabine (Heidelberg University Hospital (Alemanya)) ;
Rahmé, Ramy (Université Paris Diderot) ;
Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ;
Ghiaur, Gabriel (Johns Hopkins University) ;
Thomas, Xavier (Centre Hospitalier Lyon-Sud. Hospices Civils de Lyon) ;
Sobas, Marta (Wroclaw Medical University) ;
Guerci-Bresler, Agnes (Nancy University Hospital) ;
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Pigneux, Arnaud (Bordeaux University Hospital (França)) ;
Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Raffoux, Emmanuel (Université Paris Diderot. Hôpital Saint Louis) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Vey, Norbert (Institut Paoli Calmette) ;
de la Serna, Javier (Hospital Universitario 12 de Octubre (Madrid)) ;
Salamero, Olga (Hospital Universitari Vall d'Hebron) ;
Lengfelder, Eva (University Hospital Mannheim (Alemanya)) ;
Levis, Mark (Johns Hopkins University) ;
Fenaux, Pierre (Université Paris Diderot. Hôpital Saint Louis) ;
Sanz, Miguel A.. (Centro de Investigación Biomédica en Red de Cáncer) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Schlenk, Richard F. (German Cancer Research Center and Heidelberg University Hospital) ;
Adès, Lionel (Université Paris Diderot) ;
Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ;
Universitat Autònoma de Barcelona
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73. [...]
2020 - 10.1038/s41375-020-0758-4
Leukemia, Vol. 34 (february 2020) , p. 2333-2341
|
|
|
6.
|
|
15 p, 3.4 MB |
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
/
Kuendgen, A. (University Hospital Duesseldorf) ;
Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tuechler, H. (Boltzmann Institute for Leukemia Research. Hanusch Hospital) ;
Garcia-Manero, Guillermo (MD Anderson Cancer Center) ;
Komrokji, R. S. (H Lee Moffitt Cancer Center) ;
Sekeres, M. A. (Taussig Cancer Institute. Cleveland Clinic) ;
Della Porta, M. G. (Humanitas Research Hospital (Itàlia)) ;
Cazzola, Mario (IRCCS Policlinico San Matteo Foundation) ;
DeZern, A. E. (Johns Hopkins University. Sidney Kimmel Comprehensive Cancer Center) ;
Roboz, G. J. (Weill Cornell Medicine and The New York Presbyterian Hospital) ;
Steensma, D. P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Van de Loosdrecht, A. A. (Vrije Universiteit Amsterdam) ;
Schlenk, R. F. (Heidelberg University Hospital (Alemanya)) ;
Grau, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Blum, S. (Lausanne University Hospital) ;
Pereira, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Valent, P. (Medical University of Vienna) ;
Costa, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Giagounidis, A. (Marienhospital Duesseldorf) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Döhner, H. (University Hospital of Ulm (Alemanya)) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ;
Lübbert, M. (University Medical Center Freiburg) ;
Oiartzabal, I. (Arabako Unibertsitate Ospitalea (Vitoria, País Basc)) ;
Díez-Campelo, M. (Hospital Universitario de Salamanca) ;
Cedena, María Teresa (Hospital Universitario 12 de Octubre (Madrid)) ;
Machherndl-Spandl, S. (St Vincent's Hospital (Sydney)) ;
López-Pavía, M. (Hospital General Universitario de Valencia) ;
Baldus, C. D. (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Martinez-de-Sola, M. (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Stauder, R. (Innsbruck Medical University) ;
Merchan, B. (Hospital Universitari Vall d'Hebron) ;
List, A. (H Lee Moffitt Cancer Center) ;
Ganster, Christina (University Medical Center Göttingen) ;
Schroeder, T. (University Hospital Duesseldorf) ;
Voso, Maria Teresa (Tor Vergata University. Department of Biomedicine and Prevention) ;
Pfeilstöcker, M. (Hanusch Krankenhaus Wien) ;
Sill, H. (Medizinische Universität Graz) ;
Hildebrandt, B. (University Duesseldorf. Institute of Human Genetics) ;
Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Nomdedeu, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Cobo, Fernando (Hospital Quirón Teknon) ;
Haas, R. (University Hospital Duesseldorf) ;
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Germing, U. (University Hospital Duesseldorf) ;
Greenberg, P. L. (Stanford University Cancer Center) ;
Haase, Detlef (University Medical Center Göttingen) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Universitat Autònoma de Barcelona
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. [...]
2020 - 10.1038/s41375-020-0917-7
Leukemia, 2020
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
